MYC and plasma cell myeloma: Specifically, OTUB1 prevents ER-associated degradation of PD-L1 to contribute to immune suppression [6], inhibits Ras mono-ubiquitination to trigger lung cancer development [7], promotes RohA activation to induce prostate cancer metastasis [8], stabilizes ATF6 to facilitate bladder cancer growth [9], deubiquitinates and stabilizes FOXM1 to promote renal cell carcinoma progression [10], interacts with and stabilizes SLC7A11 to regulate ferroptosis [11], and stabilizes c-Myc to facilitate Myc-dependent multiple myeloma proliferation [12].